Background: Prasugrel is a novel third-generation thienopyridine P2Y12 receptor antagonist with more rapid, potent, and consistent platelet inhibition than clopidogrel. [23] Aim: Compare the ...

P2Y12 receptor antagonists (clopidogrel, prasugrel, ticagrelor (Brilinta, AstraZeneca) and ticlopidine) are indicated in all STEMI cases unless urgent surgery is required. Clopidogrel can also be ...

Switzerland-based Idorsia has been developing P2Y12 inhibitor selatogrel to improve outcomes in patients who suffer a second heart attack, while S1P1 receptor modulator cenerimod is in the works ...

The drug in question is cenerimod, a S1P1 receptor modulator currently in phase ... as part of the development of both cenerimod and a P2Y12 inhibitor called selatogrel. One of the knock-on ...